文献速递膀胱癌与上尿路尿路上皮癌

对新辅助化疗的反应使上尿路尿路上皮癌患者获得更好的生存结局

Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2025-01-18

本研究基于UTUC协作网络(UCAN)多中心回顾性数据库,纳入2276例接受根治性肾输尿管切除术的上尿路尿路上皮癌患者,其中378例接受新辅助化疗(NAC)。最终病理≤ypT1N0的应答者101例(26.8%),其总生存(OS)和无进展生存(PFS)显著优于无应答者。

要点

  • 378例接受NAC的患者中,101例(26.8%)达到≤ypT1N0,定义为NAC治疗应答者。
  • 应答者术后5年生存率81.5%,无应答者为59.8%。
  • 无应答者中位OS为7.0年(95%CI 5.6-9.7),中位PFS为6.0年(95%CI 4.6-9.3);应答者中位OS和PFS均未达到。

核心结论

  • 这些数据提示,NAC可在经过良好选择的、对治疗有积极反应的UTUC患者的治疗中发挥关键作用。
  • 无应答者的结局明显更差。
  • 需要更多工作来寻找反应预测因素,以改善患者选择。

研究设计与样本

  • 本研究为UTUC协作网络(UCAN)开展的多机构回顾性分析,合并了美国七家高容量三级医疗中心2276例接受根治性肾输尿管切除术的UTUC患者数据。
  • UCAN数据分析用于评估NAC反应对UTUC患者生存结局的影响。
  • UCAN数据库中共378例患者接受了NAC。

主要发现

  • 最终手术病理显示,101例患者(26.8%)为≤ypT1N0疾病,被定义为NAC治疗应答者。
  • 对NAC有反应的患者与无反应者相比,总生存(OS)和无进展生存(PFS)均显著更长。
  • 术后5年时,应答者中81.5%存活,而无应答者中为59.8%。
  • 无应答者的中位OS和PFS分别为7.0年(95%CI 5.6-9.7)和6.0年(95%CI 4.6-9.3),而应答者的中位OS和PFS未达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究的局限性包括其回顾性设计、化疗方案的异质性,以及缺乏明确规定的患者治疗选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high-risk upper tract urothelial carcinoma (UTUC) using a large, well-curated multi-institutional database. PATIENTS AND METHODS: This study was a multi-institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high-volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC. RESULTS: A total of 378 patients in the UCAN database underwent NAC. On final surgical pathology, 101 patients (26.8%) had ≤ypT1N0 disease and were defined as NAC treatment responders. Patients who responded to NAC had significantly longer overall survival (OS) and progression-free survival (PFS) compared to non-responders. At 5 years post-surgery, 81.5% of responders were alive compared to 59.8% of non-responders. The median OS and PFS times among non-responders were 7.0 years (95% confidence interval [CI] 5.6-9.7) and 6.0 years (95% CI 4.6-9.3) respectively, while the median OS and PFS were not reached among responders. Limitations of this study include its retrospective design, heterogeneity in chemotherapy regimens, and the absence of clearly defined patient selection criteria for treatment. CONCLUSION: These data suggest that NAC can play a pivotal role in the treatment of well-selected UTUC patients who respond positively. Non-responders had clearly inferior outcomes. More work is needed to find predictors of response which can improve patient selection.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yu A, Hensley PJ, Huelster HL, et al. Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU Int. 2025. PMID: 39825642. doi:10.1111/bju.16655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。